{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:23:05Z","timestamp":1769001785146,"version":"3.49.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,11,4]],"date-time":"2008-11-04T00:00:00Z","timestamp":1225756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Anti\u2010TNF agents are now widely used in Crohn\u2019s disease (CD), and in ulcerative colitis (UC).<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To review the safety profile of anti\u2010TNF agents in all patients treated with infliximab in Edinburgh from 1999 to 2007.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Complete data were available on 202\/207 patients comprising 157 CD, 42 UC and three coeliac disease. Median follow\u2010up was 2.4\u2003years (1.0\u20134.9) with a total of 620\u2003patient\u2010years follow\u2010up. About 19.1% of CD patients were subsequently treated with adalimumab.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Seven deaths (3.3%) occurred in follow\u2010up; only one death was &lt;1\u2003year post\u2010infliximab (at day 72, from lung cancer). A total of six malignancies (three haematological, three bronchogenic) and six cases of suspected demyelination (three with confirmed neurological disease) were reported. In the 90\u2003days following infliximab, 95 adverse events (36 serious) occurred in 58\/202 (28.7%) patients. In all, 42\/202 (20.8%) had an infectious event (22 serious) and 27\/202 (13.4%) of patients had an infusion reaction: 19 acute (four serious) and eight delayed (three serious).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Serious infections, malignancies and neurological disease complicate anti\u2010TNF use in clinical practice. Although evidence for causality is unclear, potential mechanisms and predisposing factors need to be explored. In individual patients, the risk\/benefit analysis needs to be carefully assessed and discussed prior to commencement of therapy.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2008.03882.x","type":"journal-article","created":{"date-parts":[[2008,11,4]],"date-time":"2008-11-04T06:40:56Z","timestamp":1225780856000},"page":"286-297","source":"Crossref","is-referenced-by-count":104,"title":["The safety profile of anti\u2010tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620\u2003patient\u2010years follow\u2010up"],"prefix":"10.1111","volume":"29","author":[{"given":"C. W.","family":"LEES","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. I.","family":"ALI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. I.","family":"THOMPSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.\u2010T.","family":"HO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. O.","family":"FORSYTHE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"MARQUEZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"COCHRANE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"AITKEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"FENNELL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"ROGERS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"SHAND","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. D.","family":"PENMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. R.","family":"PALMER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. C.","family":"WILSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. D. R.","family":"ARNOTT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"SATSANGI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,12,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.064"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.003"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03383.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.003"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60304-9"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60859-4"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.047"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.018515"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.012"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441415"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099978"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31802f6424"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03583.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099143"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0800250"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200607-995OC"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8613037"},{"issue":"1","key":"e_1_2_6_29_2","first-page":"A658","article-title":"Long term efficacy and safety of adalimumab treatment in a single centre cohort of Crohn\u2019s disease who failed to respond to Infliximab therapy","volume":"134","author":"Karmiris K","year":"2008","journal-title":"Gastroenterology"},{"issue":"4","key":"e_1_2_6_30_2","first-page":"A71","article-title":"Safety of infliximab and other Crohn\u2019s disease therapies \u2010 Treat registry data with nearly 15,000 patient\u2010years of follow\u2010up","volume":"130","author":"Lichtenstein GR","year":"2006","journal-title":"Gastroenterology"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041884"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06309"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.022"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-007-0602-z"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2008.03882.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2008.03882.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T18:28:29Z","timestamp":1697221709000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2008.03882.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,22]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1365-2036.2008.03882.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03882.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,22]]}}}